Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Eosinophilic Chronic Rhinosinusitis (MERIT)
NCT04607005Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by GSK. Started Feb 2021; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT04607005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607005.